1. Scrip
  2. >>Business
  3. >>Strategy

Guenter Stays Focused After Almirall's Annus Horribilis

 
• By Eleanor Malone

Peter Guenter, brought in from Sanofi to fix the problems at Almirall, is staying focused on 2018 as he outlines his plan to rebuild the Spanish company. Almirall will continue reallocating resources and seeking bolt-on deals to establish a sustainable dermatology business as it rolls out Skilarence and tildrakizumab in Europe.

Ships wheel
Guenter steadies the ship at Almirall • Source: Shutterstock

Almirall SA's new CEO is seeking to reassure investors he steadied the ship in 2017 and has positioned it for future growth. Announcing a 16% drop in net sales to €639m last year, Peter Guenter emphasized ongoing cost savings, new control mechanisms and a focus on dermatology growth opportunities as his tools for getting Almirall on course for success. He promised a return to growth in revenues and earnings in 2018, but wouldn't offer any longer-term targets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.